Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr−/−Mice
Open Access
- 13 June 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (6) , 1258
Abstract
Hypercholesterolemia is one of the independent risk factors for the development of cardiovascular diseases such as atherosclerosis. The treatment of hypercholesterolemia is of great significance to reduce clinical cardiovascular events and patient mortality. Simvastatin (SIM) and ezetimibe (EZE) are commonly used clinically as cholesterol-lowering drugs; however, their treatment efficacy is severely affected by their poor water solubility and low bioavailability. In this study, SIM and EZE were made into a co-amorphous system to improve their dissolution, oral bioavailability, storage stability, and cholesterol-lowering effects. The SIM-EZE co-amorphous solids (CO) were prepared successfully using the melt-quenched technique, and the physicochemical properties of CO were characterized accordingly, which exhibited improved physical stability and faster dissolution release profiles than their physical mixture (PM). In the pharmacokinetic study, the SIM-EZE CO or PM was given once by oral gavage, and mouse blood samples were collected retro-orbitally at multiple time points to determine the plasma drug concentrations. In the pharmacodynamic study, low-density lipoprotein receptor-deficient (LDLr−/−) mice were fed with a high-fat diet (HFD) for two weeks to establish a mouse model of hypercholesterolemia. Using PM as a control, we investigated the regulation of CO on plasma lipid levels in mice. Furthermore, the mice feces were collected to determine the cholesterol contents. Besides, the effect of EZE on the NPC1L1 mRNA expression level in the mouse intestines was also investigated. The pharmacokinetics results showed that the SIM-EZE CO has improved bioavailability compared to the PM. The pharmacodynamic studies showed that SIM-EZE CO significantly increased the cholesterol-lowering effects of the drugs compared to their PM. The total cholesterol excretion in the mouse feces and inhibitory effect on NCP1L1 gene expression in the mouse intestines after being given the SIM-EZE CO were more dramatic than the PM. Our study shows that the SIM-EZE CO prepared by the melt-quenched method can significantly improve the stability, bioavailability, and cholesterol-lowering efficacy with excellent development potential as a new drug formulation.Keywords
Funding Information
- National Key Research and Development Program of China (2019YFE0113500, U180312, 81872813)
- National Natural Science Foundation of China (2019YFE0113500, U180312, 81872813)
This publication has 47 references indexed in Scilit:
- Effectiveness of interventions to promote healthy diet in primary care: systematic review and meta-analysis of randomised controlled trialsBMC Public Health, 2013
- Fast dissolving eutectic compositions of curcuminInternational Journal of Pharmaceutics, 2012
- Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglyceridesColloids and Surfaces B: Biointerfaces, 2012
- Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactionsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- High Temperature- and High Pressure-Processed Garlic Improves Lipid Profiles in Rats Fed High Cholesterol DietsJournal of Medicinal Food, 2012
- Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial HypercholesterolemiaJournal of Clinical Lipidology, 2011
- The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levelsJournal of Internal Medicine, 2011
- Ezetimibe2011
- EzetimibeClinical Pharmacokinetics, 2005
- Ezetimibe/SimvastatinAmerican Journal of Cardiovascular Drugs, 2004